WPC Banner  
 


Successful Targeting of Alzheimer’s Disease Banner

Day 1  |  Day 2 |  Download Brochure

Recommended Short Courses*

Monday, June 14
9:00 am – 12:00 pm
(SC1) Reactive Metabolites in Drug Discovery and Development-A Critical Examination of the Issues

2:00 pm – 5:00 pm
(SC5) Dealing with the Blood-Brain Barrier

*Separate Registration Required.


 

WEDNESDAY, JUNE 16

12:30 pm Registration


BUILDING A BETTER MOUSE: ALZHEIMER'S DISEASE ANIMAL MODELS


1:55 Chairperson's Opening Remarks

Timothy A. Esbenshade, Senior Group Leader, Associate Fellow, Neuroscience Research, Abbott Laboratories

2:00 Recreating Full AD-like Disease Progression in Mouse Models

Carol A. Colton, Ph.D., Professor, Neurology, Duke University

Few, if any, mouse models recreate human AD pathology and lack the characteristic tau pathology and neuronal loss observed in AD. Taking advantage of the dual role of nitric oxide (NO) in innate immunity and in redox balance (two key factors in chronic neurodegeneration), we generated novel mouse models that show complete AD-like disease progression including amyloid deposition, hyperphosphorylated and aggregated normal mouse tau protein redistributed to neuronal soma, neuronal loss and robust behavioral deficits. Innate immune gene profiles also closely mimic AD. The observed disease progression suggests that species-specific differences between NOS2 in humans and mice may contribute to differences in the “sensitivity” of the brain to Aβ-mediated damage and imply a critical role for NO in AD pathogenesis.

2:30 Dysregulation of Histone Acetylation in Alzheimer's Disease

Ottavio Arancio, M.D., Ph.D., Associate Professor, Department of Pathology and Cell Biology & The Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University

Epigenetic mechanisms such as post-translational histone modifications are increasingly recognized for their contribution to gene activation and silencing in the brain. We will present data showing that an Alzheimer’s disease (AD) mouse model has a reduction in histone acetylation levels during associative memory formation. Drugs up-regulating histone acetylation rescue both the synaptic and memory phenotype in the AD mouse.

3:00 Selected Poster Presentation

Inhibition of APP Processing with HPP854, a Novel, Selective, Orally Active Inhibitor of Beta Amyloid Cleavage Enzyme (BACE), Results in Therapeutic Benefit in an Animal Model of Alzheimer’s Disease

Matthew Kostura, Ph.D., Vice President, Biology, Trans Tech Pharma

3:30 Networking Refreshment Break, Poster and Exhibit Viewing

4:30 Animal Models of Neurological Disorders in Drug Discovery Research

Jean-Cosme Dodart, Ph.D., Director, Mouse NeuroBehavior Core, Harvard NeuroDiscovery Center, Harvard Medical School

Genetically-engineered mouse (GEM) models are now widely used to support a variety of preclinical drug discovery programs, as tools for target validation, for biomarkers research or for pre-clinical proof-of-concept. In this overview, examples of GEM models of Alzheimer’s and Parkinson’s diseases will be presented, and their application to drug discovery research as well as their translational value will be discussed.

5:00 Contributions of APP Intracellular Domain (AICD) to Alzheimer’s Disease: The Evidence and the Mechanism

Sanjay W. Pimplikar, Ph.D., Assistant Staff, Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation

It is becoming clear that non-amyloid-BETA factors contribute significantly to AD pathogenesis and are potential drug targets. We earlier showed that APP IntraCellular Domain (AICD) causes AD-like pathologies in mice and its levels are increased in human AD brains. Here, we will present the mechanism of AICD-induced pathogenesis and discuss how this pathway suggests unexplored non-amyloid targets for therapeutic interventions.

5:30 KEYNOTE ADDRESS

Targeting Neurodegeneration: Genes, Biomarkers and Therapies

David BredtDavid S. Bredt, M.D., Ph.D., Vice President, Neuroscience Discovery and Clinical Investigation, Lilly Research Laboratories, Eli Lilly






6:00 End of Day


Day 1  |  Day 2 |  Download Brochure 

Submit Speaker Proposal 


WPC Agenda Download Icon

Arrow 2014 Final Brochure 


Arrow View All Sponsors

Arrow View All Media Partners 


SPONSORSHIPS & EXHIBITS

The exhibit hall has sold out the past four years, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2015, contact:

Joseph Vacca
Associate Director, Business Development
781-972-5431
jvacca@healthtech.com 

 

 

Testimonials

WPC Quotes